XERS

Xeris is a commercial-stage endocrine/neuro specialty pharma (Recorlev for Cushing's, Gvoke for severe hypoglycemia, Keveyis for periodic paralysis) that just crossed a real inflection. FY2025 revenue of $292M grew +43.7%, capping a clean four-year ramp ($49.6M→$110M→$164M→$203M→$292M) with no down years — durable, on-market product growth rather than a one-time pop. Critically, the leverage in the model is now showing: operating income jumped +174% to $24.9M (8.5% operating margin) and operating cash flow rose +177% to $28.6M, and management states in the 10-K that 2025 'is the first year we have been profitable since inception.' Generating $28.6M of operating cash while still spending $31.2M on R&D is the signature of a business approaching self-funding.

The two genuine concerns are the balance sheet and the razor-thin bottom line. Net income was just $554K (0.2% margin, diluted EPS effectively $0.00), so the 'profit' is symbolic, not yet substantive. Stockholders' equity is only $13.7M against $370M of liabilities (27x leverage) and a $671.3M accumulated deficit, with $220M of long-term debt that management notes carries an elevated cost of borrowing. However, liquidity is sound: $111M cash (+55%), current assets of $240M versus $110M current liabilities (≈2.2x current ratio), and zero current portion of debt — the debt wall is not imminent. The MD&A's caution that it 'may incur net losses' near-term and 'may continue to seek public equity and debt financing' is the standard risk, but the cash-flow trajectory makes a near-term liquidity crisis unlikely.